MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b...

MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b...


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that an abstract regarding the completed SPRINT-MS Phase 2b Trial of MN-166 in progressive multiple sclerosis , which was conducted through the National Institutes of Health -sponsored NeuroNEXT network, has been selected for plenary presentation at the American Academy of Neurology 70th Annual Meeting to be held April 21-27, 2018 in Los Angeles, California. The presentation entitled "A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis" will be presented by Dr. Robert Fox, Staff Neurologist at the Cleveland Clinic and the principal investigator of this clinical trial.



from Biotech News